Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
A Study of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT06456463
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇦🇺Royal Perth Hospital, Perth, Western Australia, Australia
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT06454409
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
- Conditions
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT06451861
- Locations
- 🇨🇳
Foshan First People's Hospital, Foshan, Guangdong, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-06-10
- Target Recruit Count
- 20
- Registration Number
- NCT06449482
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06448013
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
- Conditions
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 78
- Registration Number
- NCT06445959
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT06445907
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 34
- Registration Number
- NCT06434662
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 30
- Registration Number
- NCT06429449
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-05-24
- Target Recruit Count
- 40
- Registration Number
- NCT06429098
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu, China
🇨🇳Ethical Committee of the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.